Tabletted prepn.

A technology of composition and tablet, which is applied in the field of tablet composition and can solve the problems of reduced bioavailability and the like

Inactive Publication Date: 2000-01-26
EA PHARMA CO LTD
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, it is known that when the compound [1] is orally administered before or after a meal for the purpose of suppressing a rise in blood sugar after a meal, its bioavailability decreases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tabletted prepn.
  • Tabletted prepn.

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Each component shown in Table 1 was weighed, and each component except magnesium stearate was mixed for 10 minutes with the stirring granulator. Next, add pure water (15-75 parts by weight) that can produce particles with a particle diameter of about 100-500 μm, and perform stirring and granulation for 10 minutes. All granules were crushed with a crusher and dried. Add magnesium stearate to the obtained dry granules, mix with a V-type mixer for 2 minutes, and compress to form a tablet with a diameter of 7 mm, a thickness of 3 mm, and a weight of 100 mg. The disintegration time of the obtained tablet in water was tested according to the disintegration test method of the Japanese Pharmacopoeia. Also, L-HPC (LH-31) [10 to 12.9% by weight of hydroxypropoxyl group, average particle diameter of 30 μm or less] manufactured by Shin-Etsu Chemical Co., Ltd. was used as low-substituted hydroxypropyl cellulose. The results are shown in Table 1.

[0024] Comparative pr...

Embodiment 2

[0026] 250 g of compound [1], 530 g of lactose, and 200 g of low-substituted hydroxypropyl cellulose [LH-31 manufactured by Shin-Etsu Chemical Co., Ltd., 10.0 to 13.0% by weight of hydroxypropoxy, and an average particle size of 30 μm or less) , after fully stirring in the stirring and mixing granulator, add 10 grams of hydroxypropyl cellulose [Nippon Soda (KK) HPC-L] dissolved in 500 grams of pure water and carry out stirring and granulation. After the obtained granules were crushed and dried, 10 grams of magnesium stearate was added and tableted to obtain a tablet with a diameter of 7 mm, a thickness of 3.7 mm, a weight of 120 mg, and a tablet containing 30 mg of compound [1]. The tablet was sprayed with a coating liquid composed of 8 g of hydroxypropyl methylcellulose, 1.5 g of polyethylene glycol 6000, 2.4 g of talc, 0.5 g of titanium oxide and 87.6 g of pure water to obtain coated tablets. Comparative example 1

Embodiment 3

[0032] 330 grams of compound [1], 450 grams of lactose and 200 grams of oligomeric hydroxypropyl cellulose [LH-31 produced by Shin-Etsu Chemical Industry Co., Ltd.] were fully stirred in a mixing granulator, and then added and dissolved in 500 10 grams of hydroxypropyl cellulose [Nippon Soda (KK) HPC-L] in gram pure water and carry out stirring granulation. After the obtained granules were crushed and dried, 10 grams of magnesium stearate was added and tabletted to obtain a tablet with a diameter of 7 mm, a thickness of 3.7 mm, a weight of 121 mg, and a tablet containing 40 mg of compound [1]. The tablet was sprayed with a coating liquid composed of 8 grams of hydroxypropyl methylcellulose, 1.5 grams of polyethylene glycol 6000, 2.4 grams of talc, 0.5 grams of titanium oxide and 87.6 grams of pure water to obtain coated tablets.

[0033]For the obtained coated tablet, the influence of food on the oral absorbability was evaluated in the same manner as described above. As a resu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Thicknessaaaaaaaaaa
Login to view more

Abstract

A tablet composition containing N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and a disintegrator selected from the group consisting of sodium carboxymethyl cellulose, calcium carboxymethyl cellulose and croscarmellose sodium is disclosed. This tablet composition is rapidly disintegrated in the stomach after the administration and absorbed without being influenced by meals to inhibit the rise of the blood sugar levels of diabetics after meals.

Description

technical field [0001] The present invention relates to a tablet composition for controlling the blood sugar level of diabetic patients. Background of the invention [0002] The following formula is known: The shown N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine (hereinafter referred to as compound [1]) exhibits an excellent blood sugar lowering effect when administered orally. It can be used as a therapeutic agent for diabetes (Japanese Patent Publication No. 4-15221, hereinafter referred to as "J.P. KOKOKU"). [0003] However, it is known that when the compound [1] is orally administered before or after a meal for the purpose of suppressing a rise in blood sugar after a meal, its bioavailability decreases. Contents of the invention [0004] The object of the present invention is to provide a tablet composition exhibiting a blood sugar lowering effect with a short duration of effective time, which is rapidly absorbed without being affected by diet, and does n...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61K9/28A61K9/36A61K31/195A61K31/198A61K47/38A61P3/08
CPCA61K9/2853Y10S514/866A61K9/2054A61K9/2866A61K31/198A61K31/195A61P3/10A61P3/08
Inventor 矢吹昭戒田正人安藤隆彦二宫信豪尾崎正尚
Owner EA PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap